Dyne Therapeutics Announces Key Leadership Appointments
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
- Wall Street ends higher as Fed holds key rate steady, focus turns to earnings
- SK Hynix shares surge after Q3 profit beats expectations
- Oil prices rise on Yemen fighting, Saudi refinery attack
- Alphabet stock rises as OpenAI plans to buy Google's TPUs
- Wendy's shares surge 16% on $1.4 billion takeover bid by Nelson Peltz’s Trian Fund
- ServiceNow (NOW) Misses Q3 EPS by 2c, Beats on Revenue; Offers Q4 Revenue Guidance
- Oracle sets $225 billion revenue target for FY30 at investor day
- Rivian shares slip ahead of Thursday earnings release
- Marvell in advanced talks to acquire Lumentum, Bloomberg reports
- SpaceX stock drops amid spaceport lawsuit, debt concerns
Oppenheimer Reiterates Outperform Rating on Dyne Therapeutics (DYN)
September 3, 2024 11:45 AM EDTOppenheimer analyst Francois Brisebois reiterated an Outperform rating and $55.00 price target on Dyne Therapeutics (NASDAQ: DYN).
The analyst comments "DYN reported new clinical data from its P1/2 DYNE-251 for DMD dose optimization studies. In addition to dose-dependent PMO delivery to muscle and exon... More



